Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

NCT00048347 | Completed Phase 2 Results

• 2 other identifiers: 03001903-I-0019
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the safety and effectiveness of the drug interferon-beta1a (AVONEX) in treating ulcerative colitis and examine the drug's effect on the immune system. People with ulcerative colitis have increased amounts of inflammatory chemicals (cytokines) made by immune cells in the lining of the colon. Studies have shown that interferon-beta may block the activity of these cytokines. Interferon-beta1a (AVONEX) is currently FDA-approved to treat multiple sclerosis, a disease involving inflammation of the brain and spinal cord. Patients 18 years of age and older who have had ulcerative colitis for at least 4 months may be eligible for this study. Candidates will be screened with a review of their medical records, a medical history and physical examination, electrocardiogram (EKG), blood, urine, and stool tests, and a pregnancy test for women of childbearing potential. A colonoscopy will also be done to determine disease activity and extent. This test uses a lighted tube to examine the amount of inflammation in the colon and take tissue samples (biopsies) for testing. Before the test, the patient is given a medicine to allay anxiety and the discomfort of inserting the endoscope into the rectum. This flexible tube allows the doctor to see the intestinal mucosa and project an image of the inner lining of the intestine onto a TV monitor. At various places in the intestine, small pieces of tissue are plucked out by a special device at the tip of the endoscope. The procedure generally lasts 30 minutes to 1 hour. Participants will come to the NIH Clinical Center once a week for 4 weeks to receive an injection of interferon-beta, fill out questionnaires, and have a symptoms check, physical examination, and blood tests. Patients whose colitis has not worsened at the end of the 4 weeks and who have not had significant drug side effects will continue to receive weekly injections for an additional 8 weeks. Some patients may receive some of the last eight injections outside of NIH, but all patients will visit the Clinical Center visits every 3 to 4 weeks for a physical exam, symptoms check and blood tests. After the 12 injections are completed, patients will have another colonoscopy to evaluate the response to treatment and will return to the Clinical Center every 6 weeks for a total of four visits, for a physical examination, symptoms check and blood tests.

Conditions

Ulcerative Colitis

Keywords

Lymphocyte; Monocyte; Inflammation; Th2; Colonoscopy; Ulcerative Colitis

Outcome Measures

Primary Outcomes (1)

• Percent of Participants With at Least a 3 Point Drop in the Short Clinical Colitis Score (SCCAI)

  The primary endpoint is the percent of patients with a clinical response as defined by a drop in the Short Clinical Colitis Score (SCCAI) of at least 3 points from Week 0 to Week 12. Short Clinical Colitis Score (SCCAI): Bowel frequency(day0-3,night0-2),urgency(0-3),rectal bleeding(0-3),well being(0-4),extracolonic features(0-4), total score 0(best)-19(worst).

  Baseline, Week 12

Study Arms (1)

Avonex

EXPERIMENTAL

Interferon-beta1a (Avonex) 30 µg IM every week for 12 weeks

Drug: AVONEX

Interventions

AVONEX DRUG

30µg IM every week for 12 weeks

Avonex

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years old or greater.
• Diagnosis of ulcerative colitis for at least 4 months based on endoscopic appearance or radiographic distribution of disease and corroborated with histopathology (especially the absence of granulomata).
• Presence of current active disease as defined by a Simple Clinical Colitis Activity Index of greater than or equal to 5 (for either of the two measurements done during the Screening Phase and that the second measurement is within 50 percent of the value of the first) who may or may not have the presence of one of the following: current corticosteroid- dependence for disease treatment, disease refractory to corticosteroids, or history of intolerance to treatment with corticosteroids (for criterion of co-administered corticosteroid dose see below).
• Corticosteroid-dependence is defined as relapse of ulcerative colitis within 60 days of completing a course of corticosteroid treatment, or during corticosteroid tapering at doses greater than or equal to 10 mg prednisone/day (or equivalent), or within three months following corticosteroid tapering while receiving a steroid dose of greater than or equal to 10 mg prednisone/day (or equivalent).
• If currently receiving medication for ulcerative colitis, patients may be on a stable regimen of one or a combination of the following drug doses and durations:
• Corticosteroids (less than or equal to 25 mg Prednisone/d or Prednisone equivalent) is greater than or equal to 4 weeks;
• ASA/Sulfasalazine is greater than or equal to 4 weeks;
• Azathioprine/6-MP/thioguanine is greater than or equal to 12 weeks. (Note: Patients receiving azathioprine/6-MP/thioguanine must have been on a stable dose of this medication for greater than or equal to 8 weeks before randomization);
• Probiotics (live bacterial dietary supplements) greater than or equal to 4 weeks;
• Prebiotics (dietary supplements to produce biologically active substances) greater than or equal to 4 weeks.
• \. Use of barrier or hormonal methods of birth control for female subjects who are not surgically sterile or postmenopausal.
• \. Negative serum beta-hCG for women of child-bearing potential (women who are not surgically sterile or postmenopausal) to exclude early unnoticed pregnancy.
• \. Negative results on stool examination for culture of enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, Vibrio, E. coli O157/H7), Clostridium difficile toxin assay, enteric parasites and their ova (including Giardia and Cryptosporidia).
• \. Thyroid function test and TSH level within establish normal range set by the Clinical Center.

You may not qualify if:

• Use of any of the following medications within the specified time period prior to the first dose of interferon-beta or at any time during the study:
• Non-steroidal anti-inflammatory agents (including COX-2 inhibitors), - 1 week
• Corticosteroids (greater than 25 mg Prednisone/d or Prednisone equivalent), Methotrexate, Cyclosporin, Tacrolimus, Thalidomide, or Mycophenolate mofetil - 4 weeks
• Monoclonal antibodies to TNF alpha or any Other Biologic (cytokine, anti-cytokine, or integrin-based therapy, for instance) - 4 months
• Any experimental agent - 1 month
• Concomitant use of any of the following drugs: isoniazid, iproniazid, dantrolene, ticrynafen (tienilic acid), ibufenac, bromfenac, benoxaprofen, zileutan, nicotinic acid, trovafloxacin, perhexiline, dilevavol, labetalol, pemoline, felbamate, tolcapone, diclofenac, AIDS drugs (HIV+ subjects are excluded anyway), and troglitozone.
• History of colectomy, partial colectomy, current ostomy, or pouchitis.
• Presence of significant electrocardiogram abnormalities including QT(c) greater than or equal to 0.48 sec, Mobitz type II second degree or third degree atrioventricular block, left bundle branch block or right bundle branch block accompanied by any fascicular block, changes consistent with acute ischemia or pericarditis.
• Presence of a diagnosis of Crohn's disease, indeterminate colitis, microscopic colitis, ischemic colitis, or colitis attributable to infection. This determination may require use of clinical, endoscopic, and histologic data.
• Presence of Cushing's syndrome.
• Presence of current active bowel obstruction, intestinal perforation, significant GI hemorrhage, known presence of high grade stricture, history of toxic megacolon, history of colonic epithelium high-grade dysplasia or a dysplasia-associated lesion or mass that does not resemble an adenoma (that is a mass lesion, stricture, or broad-based tumor).
• Anticipation that surgery may be required to treat the ulcerative colitis within 3 months of study entry.
• HIV positivity or signs and symptoms consistent with HIV infection.
• Acute systemic or intestinal infection requiring antibiotics.
• Active hepatitis B or C.

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (1)

• Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut. 1999 Jun;44(6):812-8. doi: 10.1136/gut.44.6.812.

  PMID: 10323882 BACKGROUND

MeSH Terms

Conditions

Colitis, Ulcerative; Inflammation

Interventions

Interferon beta-1a

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Interferon-beta; Interferon Type I; Interferons; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Limitations and Caveats

While this study was designed as a proof-of-concept pilot trial to correlate changes in IL-13 and other cytokines with clinical response, efficacy was measured. The efficacy estimate is limited by the open-label design.

Results Point of Contact

• Title: Peter Mannon, MD
• Organization: NIAID

pmannon@uab.edu

205-934-4726

Study Officials

• Peter J Mannon, MD

  National Institutes of Health (NIH)

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH

Study Record Dates

• First Submitted: October 29, 2002
• First Posted: October 30, 2002
• Study Start: October 1, 2002
• Primary Completion: June 1, 2008
• Study Completion: May 1, 2010
• Last Updated: September 8, 2010
• Results First Posted: August 31, 2010

Record last verified: 2010-08

Locations

US (1)